Neurobiological Technologies to hold up to 50% of acute ischemic stroke trials outside United States

By Lisa Kerner

Erie, Pa., May 4 - Neurobiological Technologies, Inc. said it plans to conduct its phase 3 acute ischemic stroke trials for Viprinex, Ancrod Stroke Program I (ASP-I) and Program II (ASP-II), at up to 130 sites worldwide.

The company expects up to 30% of the ASP-1 trials and 50% of the ASP-II trials to take place outside of the United States.

Each double-blind, randomized, placebo-controlled trial will enroll 650 patients, each receiving a brief intravenous infusion of Viprinex or a placebo within six hours of stroke onset.

Neurobiological Technologies is a drug development company located in Emeryville, Calif.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.